Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

474 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Quality of life outcomes of combination zidovudine- didanosine-nevirapine and zidovudine-didanosine for antiretroviral-naive advanced HIV-infected patients.
Bucciardini R, Wu AW, Floridia M, Fragola V, Ricciardulli D, Tomino C, Weimer LE, Pirillo MF, Mirra M, Marzi M, Giannini G, Galluzzo CM, Andreotti M, Massella M, Vella S; Istituto Superiore di Sanità 047 Study. Bucciardini R, et al. Among authors: andreotti m. AIDS. 2000 Nov 10;14(16):2567-74. doi: 10.1097/00002030-200011100-00020. AIDS. 2000. PMID: 11101069 Clinical Trial.
Hospitalizations and costs of treatment for protease inhibitor-based regimens in patients with very advanced HIV-infection (CD4 < 50/mm(3)).
Floridia M, Massella M, Bucciardini R, Perucci CA, Rossi L, Tomino C, Fragola V, Ricciardulli D, Galluzzo CM, Giannini G, Pirillo MF, Andreotti M, Mirra M, Vella S. Floridia M, et al. Among authors: andreotti m. HIV Clin Trials. 2000 Sep-Oct;1(2):9-16. doi: 10.1310/6ulm-xyb7-h4xp-bhfj. HIV Clin Trials. 2000. PMID: 11590493 Clinical Trial.
HIV-related morbidity and mortality in patients starting protease inhibitors in very advanced HIV disease (CD4 count of < 50 cells/microL): an analysis of 338 clinical events from a randomized clinical trial.
Floridia M, Fragola V, Galluzzo CM, Giannini G, Pirillo MF, Andreotti M, Tomino C, Vella S. Floridia M, et al. Among authors: andreotti m. HIV Med. 2002 Apr;3(2):75-84. doi: 10.1046/j.1468-1293.2002.00104.x. HIV Med. 2002. PMID: 12010353 Free article. Clinical Trial.
Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/microL).
Floridia M, Bucciardini R, Fragola V, Galluzzo CM, Giannini G, Pirillo MF, Amici R, Andreotti M, Ricciardulli D, Tomino C, Vella S; ISS-IP1 study group. Floridia M, et al. Among authors: andreotti m. HIV Med. 2004 Jan;5(1):1-10. doi: 10.1111/j.1468-1293.2004.00177.x. HIV Med. 2004. PMID: 14731162 Free article. Clinical Trial.
Interleukin-15 production by monocyte-derived dendritic cells and T cell proliferation in HIV-infected patients with discordant response to highly active antiretroviral therapy.
d'Ettorre G, Forcina G, Andreotti M, Sarmati L, Palmisano L, Andreoni M, Vella S, Mastroianni CM, Vullo V. d'Ettorre G, et al. Among authors: andreotti m. Clin Exp Immunol. 2004 Feb;135(2):280-5. doi: 10.1111/j.1365-2249.2004.02373.x. Clin Exp Immunol. 2004. PMID: 14738457 Free PMC article.
Development of a human immunodeficiency virus vector-based, single-cycle assay for evaluation of anti-integrase compounds.
Bona R, Andreotti M, Buffa V, Leone P, Galluzzo CM, Amici R, Palmisano L, Mancini MG, Michelini Z, Di Santo R, Costi R, Roux A, Pommier Y, Marchand C, Vella S, Cara A. Bona R, et al. Among authors: andreotti m. Antimicrob Agents Chemother. 2006 Oct;50(10):3407-17. doi: 10.1128/AAC.00517-06. Antimicrob Agents Chemother. 2006. PMID: 17005823 Free PMC article.
474 results